Bascom Palmer Eye Institute invites you to join us in February 2017 for our fourteenth annual angiogenesis meeting. This unique and exciting symposium entitled **Angiogenesis, Exudation, and Degeneration 2017** will be held February 11, 2017 at the Mandarin Oriental Hotel in Miami, Florida. The meeting will feature an exceptional gathering of basic scientists, clinicians, and healthcare experts, all focused on understanding and treating neovascular and exudative diseases of the eye. The meeting will highlight the revolutionary pharmacotherapies now in development and clinical practice for the management of neovascular AMD, macular edema, diabetic retinopathy, and retinopathy of prematurity with a special emphasis on the present and future financial impact of these drugs on clinical practices and Medicare.
COURSE CO-DIRECTORS

Philip J. Rosenfeld, MD, PhD
Professor of Ophthalmology
University of Miami Miller School of Medicine
Course Co-Director

Harry W. Flynn, Jr., MD
Professor of Ophthalmology
The J. Donald M. Gass Distinguished Chair in Ophthalmology
University of Miami Miller School of Medicine
Course Co-Director

Carmen A. Puliafito, MD, MBA
Voluntary Professor of Ophthalmology
Bascom Palmer Eye Institute
University of Miami Miller School of Medicine
Course Associate Director

COURSE DESCRIPTION
Angiogenesis 2017 follows the tradition of excellence established by the widely acclaimed Angiogenesis programs between 2004 and 2016. Designed for retinal specialists, general ophthalmologists and researchers, the current program will review the latest therapies for exudative eye diseases and the use of these new treatments in clinical practice. We will emphasize current and future treatments for a broad spectrum of retinal diseases with special emphasis on age-related macular degeneration and diabetic retinopathy.

COURSE OBJECTIVES
Upon completion of this program, participants should be able to:

- Enhance patient care by evaluating the current global use of anti-VEGF drugs for exudative ocular diseases
- Manage patients with anti-VEGF therapy through the preferred dosing practices
- Improve management skills by evaluating all the risks associated with injections of an anti-VEGF drugs
- Analyze the rationale for emerging treatments for different macular and retinal degenerative conditions
- Analyze results of clinical trials in exudative and non-exudative macular diseases and apply to clinical practice
- Evaluate the benefits and limitations of combination therapies for exudative macular diseases
- Evaluate the benefits and limitations of different imaging strategies for macular diseases
- Understand the emerging imaging technology known as OCT angiography
- Enhance patient care by analyzing the genetic basis for different macular and retinal degenerative conditions
7:00 am Registration and Continental Breakfast

7:55 Welcome and Overview
Philip J. Rosenfeld, MD, PhD; Harry W. Flynn, Jr., MD; and Carmen A. Puliafito, MD, MBA

SESSION I: Age-Related Macular Degeneration
Moderator: Philip J. Rosenfeld, MD, PhD

8:00 Genetics and Nutrition in AMD
Emily Y. Chew, MD

8:10 The Oil Spill Strategies for AMD: Update and Model System
Christine A. Curcio, PhD, FARVO

8:20 Cuticular Drusen: New Clinical Pathological Observations
Lawrence A. Yannuzzi, MD

8:30 Update from CAM: A Proposed Classification System for Atrophy
Srinivas R. Sadda, MD

8:40 Using AMD Geographic Atrophy Area as a Clinical Trial Primary Outcome Variable
Frederick L. Ferris, III, MD

9:00 Mechanisms of Low Luminance Vision Loss in AMD
Karl G. Csaky, MD, PhD

9:10 Computational Approaches to Modeling Compromise in the Choroidal Circulation
Philip Luthert, MB BS

9:20 Choriocapillaris Death is an Early Event in Neovascular AMD
Gerard A. Lutty, PhD

SESSION II: OCT Angiographic Imaging
Moderator: Carmen A. Puliafito, MD, MBA

9:30 The Role of the Choriocapillaris in Non-Exudative AMD: An OCT Angiography Based Evaluation
Nadia Waheed, MD

9:40 SS-OCT Angiographic Imaging of the Choriocapillaris in AMD
Fang Zheng, MD

9:50 VISTA – Making OCTA Quantifiable
Jay S. Duker, MD

10:00 OCT Angiographic Prevalence and Natural History of Non-Exudative Neovascular AMD
Joao Rafael De Oliveira Dias, MD

10:10 SD-OCTA vs. SS-OCTA Imaging of CNV in AMD
Philip J. Rosenfeld, MD, PhD

10:20 Biomarkers of Neovascular Activity Using OCT Angiography
David Sarraf, MD
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30</td>
<td>Top Innovations in Retina – A VC’s Perspective</td>
<td>Emmett T. Cunningham, Jr., MD, PhD, MPH</td>
</tr>
<tr>
<td>10:40</td>
<td>Lipids as Therapeutic Targets in Dry AMD</td>
<td>Rajendra S. Apte, MD, PhD</td>
</tr>
<tr>
<td>10:50</td>
<td>Macrophage Polarization as Therapeutic Target in Dry AMD</td>
<td>Shelley Boyd, MD, FRCS</td>
</tr>
<tr>
<td>11:00</td>
<td>Update of Elamipretide (MTP-131) for Dry AMD</td>
<td>Scott W. Cousins, MD</td>
</tr>
<tr>
<td>11:10</td>
<td>Complement C3 Inhibition in AMD</td>
<td>Cedric G. Francois, MD, PhD</td>
</tr>
<tr>
<td>11:20</td>
<td>Development of a MAC Inhibitor for Dry AMD Using a Gene Therapy Approach</td>
<td>Elias Reichel, MD</td>
</tr>
<tr>
<td>11:30</td>
<td>Intravitreal Approaches to Retinal Gene Therapy: Results from Second Generation Vectors and Molecules</td>
<td>David M. Brown, MD, FACS</td>
</tr>
<tr>
<td>11:40</td>
<td>Technical Aspects of Gene Delivery in AMD by Sub Retinal Surgical Approaches: Imaging Results and the Efficacy Impact of Location of Injection and Choice of Agent</td>
<td>Szilárd Kiss, MD</td>
</tr>
<tr>
<td>11:50</td>
<td>A Sustained Release Liposomal Delivery System</td>
<td>Peter K. Kaiser, MD</td>
</tr>
<tr>
<td>12:00</td>
<td>Incidence of New Choroidal Neovascularization in Fellow Eyes of Patients Treated in the VIEW Trials</td>
<td>K. Bailey Freund, MD</td>
</tr>
<tr>
<td>12:10</td>
<td>Long Term Outcomes in Patients Treated for Neovascular AMD</td>
<td>Daniel F. Martin, MD</td>
</tr>
<tr>
<td>12:20</td>
<td>Progression Rate of RPE Loss in Patients with Neovascular AMD Treated with Different VEGF Inhibitors</td>
<td>Stephan Michels, MD, MBA</td>
</tr>
<tr>
<td>12:30</td>
<td>Long-Term Treatment with Intravitreal Aflibercept Injection in Patients Completing the VIEW and VIEW1 Extension Studies: Two Year Results of the RANGE Study</td>
<td>W. Lloyd Clark, MD</td>
</tr>
<tr>
<td>12:40</td>
<td>Functional and Anatomic Outcomes 1 Year Following Conversion to Conbercept in Chinese Patients with Neovascular Age-Related Macular Degeneration: A Case Series study</td>
<td>Xiaodong Sun, MD</td>
</tr>
<tr>
<td>12:50</td>
<td>Brolucizumab vs. Aflibercept Treatment for Neovascular AMD</td>
<td>Lawrence J. Singerman, MD, FACS</td>
</tr>
<tr>
<td>Time</td>
<td>Session/Topic</td>
<td>Speaker</td>
</tr>
<tr>
<td>-------</td>
<td>-----------------------------------------------------------------------------</td>
<td>--------------------------------</td>
</tr>
<tr>
<td>1:00</td>
<td>Risk Factors for Fibrosis in the Anti-VEGF Era</td>
<td>Usha Chakravarthy, MD</td>
</tr>
<tr>
<td>1:10</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>2:00</td>
<td>SESSION V: Neovascular AMD: Combination Therapies</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderator: Carmen A. Puliafito, MD, MBA</td>
<td></td>
</tr>
<tr>
<td>2:00</td>
<td>Anti-PDGF Therapy for Neovascular AMD</td>
<td>Pravin U. Dugel, MD</td>
</tr>
<tr>
<td>2:10</td>
<td>Morphology-Visual Acuity Correlations after anti-VEGF/anti-PDGF Therapy for Neovascular AMD</td>
<td>Glenn J. Jaffe, MD</td>
</tr>
<tr>
<td>2:20</td>
<td>Combination Therapy with Aflibercept for the Treatment of Neovascular AMD</td>
<td>Jeffrey S. Heier, MD</td>
</tr>
<tr>
<td>2:30</td>
<td>Icon-1 in the Treatment of Neovascular AMD: Phase 2a Study Results</td>
<td>Carl D. Regillo, MD, FACS</td>
</tr>
<tr>
<td>2:40</td>
<td>Topical Squalamine for Neovascular AMD: An Update</td>
<td>Jason S. Slakter, MD</td>
</tr>
<tr>
<td>2:50</td>
<td>SESSION VI: Stem Cells and Retinal Degenerations</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderator: Wen-Hsiang Lee, MD, PhD</td>
<td></td>
</tr>
<tr>
<td>2:50</td>
<td>Patient-Funded Stem Cell Therapies: A Report of Three Cases and Their Clinical and Regulatory Context</td>
<td>Thomas A. Albini, MD</td>
</tr>
<tr>
<td>3:00</td>
<td>Long-Term Outcomes of hESC-Derived RPE Cell Transplantation in Atrophic AMD and Stargardt Disease</td>
<td>Ninel Z. Gregori, MD</td>
</tr>
<tr>
<td>3:10</td>
<td>Stem Cell Derived RPE Transplantation - An Update of the London Project</td>
<td>Lyndon da Cruz, MD</td>
</tr>
<tr>
<td>3:20</td>
<td>Embryonic Stem cell-Derived RPE: The California Project, A Phase 1/2a Clinical Trial</td>
<td>David R. Hinton, PhD</td>
</tr>
<tr>
<td>3:30</td>
<td>Subretinal Transplantation of RPE Cells Derived from Human Embryonic Stem Cells in Patients with Advanced Dry AMD: Observations from the Hadassah Phase I/IIa Clinical Trial</td>
<td>Eyal Banin, MD, PhD</td>
</tr>
<tr>
<td>3:40</td>
<td>Autologous iPSC-RPE Cell Therapy for AMD</td>
<td>Kapil Bharti, PhD</td>
</tr>
<tr>
<td>3:50</td>
<td>Toward More Precise Sub Retinal Therapeutic Delivery: New Techniques and Instrumentation</td>
<td>Allen C. Ho, MD</td>
</tr>
<tr>
<td>4:00</td>
<td>Clinical Translation of Retinal Progenitors Cells for RP: The jCyte Experience</td>
<td>Henry J. Klassen, MD, PhD</td>
</tr>
<tr>
<td>4:10</td>
<td>Update on Clinical Trials for Retinal Degenerations</td>
<td>Byron L. Lam, MD</td>
</tr>
<tr>
<td>Time</td>
<td>Session Title</td>
<td>Presenter</td>
</tr>
<tr>
<td>-------</td>
<td>---------------------------------------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>4:20</td>
<td>DRCR.net Update</td>
<td>Harry W. Flynn, Jr., MD</td>
</tr>
<tr>
<td>4:30</td>
<td>Slurry Kenalog: A Lower Cost, Quick and Easy Alternative for Long-Term Intraocular Steroid Delivery</td>
<td>Susan M. Malinowski, MD</td>
</tr>
<tr>
<td>4:40</td>
<td>Update on Aflibercept Pharmacokinetics and Treatment of Diabetic Macular Edema</td>
<td>Diana V. Do, MD</td>
</tr>
<tr>
<td>4:50</td>
<td>Ziv-Aflibercept in Diabetic Macular Edema</td>
<td>Michel E. Farah, MD</td>
</tr>
<tr>
<td>5:00</td>
<td>ENDURANCE Extension Study Following the VISTA DME Study</td>
<td>Charles C. Wykoff, MD, PhD</td>
</tr>
<tr>
<td>5:10</td>
<td>Peripheral and Macular Retinal Vascular Perfusion and Leakage Dynamics in Diabetic Macular Edema and Retinal Venous Occlusions During Intravitreal Aflibercept Injection (IAI) Treatment for Retinal Edema: PERMEATE Study</td>
<td>Justis P. Ehlers, MD</td>
</tr>
<tr>
<td>5:20</td>
<td>Anti-Integrin Treatment for Diabetic Edema</td>
<td>David S. Boyer, MD</td>
</tr>
<tr>
<td>5:30</td>
<td>Impact of Cataract Surgery on Visual Acuity and OCT in DME Patients Undergoing Anti-VEGF Therapy</td>
<td>Andrew A. Moshfeghi, MD, MBA</td>
</tr>
<tr>
<td>5:40</td>
<td>Intravitreal Sirolimus for Non-Infectious Uveitis: Primary Outcomes of the Phase3 SAKURA 2 Study</td>
<td>Quan D. Nguyen, MD, MSc</td>
</tr>
<tr>
<td>5:50</td>
<td>Suprachoroidal Triamcinolone Acetonide for Retinal Vein Occlusion: Results of the Tanzanite Trial</td>
<td>Peter A. Campochiaro, MD</td>
</tr>
<tr>
<td>6:00</td>
<td>MacTel Project Update</td>
<td>Martin Friedlander, MD, PhD</td>
</tr>
<tr>
<td>6:10</td>
<td>Near-Term Safety of Bevacizumab in Treatment of Retinopathy of Prematurity</td>
<td>Darius M. Moshfeghi, MD</td>
</tr>
<tr>
<td>6:20</td>
<td>Advances in Mobile Device Enabled Retinal Fundus Photography for Clinical Research and Public Health Screening</td>
<td>Mark S. Blumenkranz, MD</td>
</tr>
<tr>
<td>6:30</td>
<td>Adjourn/Cocktail Reception</td>
<td></td>
</tr>
</tbody>
</table>
Thomas A. Albini, MD  
Associate Professor of Clinical Ophthalmology  
Bascom Palmer Eye Institute  
University of Miami Miller School of Medicine  
Miami, FL

Rajendra S. Apte, MD, PhD  
Paul A. Cibis Distinguished Professor of Ophthalmology & Visual Science  
Washington University School of Medicine  
St. Louis, MO

Eyal Banin, MD, PhD  
Professor of Ophthalmology  
Director, Center for Retinal and Macular Degenerations  
Hadassah-Hebrew University Medical Center  
Jerusalem, Israel

Kapil Bhati, PhD  
Earl Stadtmann Tenure-Track Investigator  
National Eye Institute/National Institutes of Health  
Bethesda, MD

Mark S. Blumenkranz, MD  
H.J. Smead Professor of Ophthalmology  
Director of the Ophthalmic Innovation Program  
Byers Eye Institute  
Stanford University  
Palo Alto, CA

Shelley Boyd, MD, FRCS  
Assistant Professor & Clinician-Scientist  
Keenan Research Centre, St. Michael’s Hospital  
Dept. of Ophthalmology & Vision Science  
University of Toronto  
Toronto, Ontario, Canada

David S. Boyer, MD  
Clinical Professor of Ophthalmology  
Keck School of Medicine  
University of Southern California  
Senior Partner, Retina-Vitreous Associates  
Los Angeles, CA

David M. Brown, MD, FACS  
Clinical Professor of Ophthalmology  
Baylor College of Medicine  
Director of Clinical Research  
Retina Consultants of Houston  
Houston, TX

Peter A. Campochiaro, MD  
George S. and Dolores Eccles Professor of Ophthalmology and Neuroscience  
Wilmer Eye Institute  
The Johns Hopkins University School of Medicine  
Baltimore, MD

Usha Chakravarthy, MD  
Professor of Ophthalmology and Visual Sciences  
Queen’s University of Belfast  
Northern Ireland, United Kingdom

Emily Y. Chew, MD  
Deputy Director, Division of Epidemiology and Clinical Applications  
National Eye Institute/National Institutes of Health  
Bethesda, MD

W. Lloyd Clark, MD  
Assistant Clinical Professor of Ophthalmology  
University of South Carolina School of Medicine  
Palmetto Retina Center, LLC  
West Columbia, SC

Scott W. Cousins, MD  
Robert Machemer, MD, Professor of Ophthalmology and Immunology  
Vice Chair for Research  
Director, Duke Center for Macular Diseases  
Duke Eye Center, Duke University  
Durham, NC

Karl G. Casyky, MD, PhD  
T. Boone Pickens Director  
Clinical Center of Innovation for AMD  
Managing Director and Chief Medical Officer  
Retina Foundation of the Southwest  
Partner, Retina Consultants of Arizona  
Palo Alto, CA

Emmett T. Cunningham, Jr., MD, PhD, MPH  
Director, The Uveitis Service, California Pacific Medical Center  
Adjunct Clinical Professor of Ophthalmology  
Stanford University School of Medicine  
Research Associate, The Francis I. Proctor Foundation, UCSF  
Partner, West Coast Retina Medical Group  
Hillsborough, CA

Christine A. Curcio, PhD, FARVO  
Professor of Ophthalmology  
Director, Age-related Maculopathy Histopathology Laboratory  
University of Alabama School of Medicine  
EyeSight Foundation Vision Research Labs  
Birmingham, AL

Professor Lyndon da Cruz  
Professor of Stem Cell and Retinal Transplantation Surgery  
Institute of Ophthalmology, UCL, London  
Consultant Retinal Surgeon, Moorfields Eye Hospital  
London, UK

Joao R. De Oliveira Dias, MD  
Post-Doctoral Associate  
Bascom Palmer Eye Institute  
Miami, FL

Diana V. Do, MD  
Professor of Ophthalmology  
Byers Eye Institute  
Stanford University School of Medicine  
Palo Alto, CA

Pravin U. Dugel, MD  
Clinical Professor of Ophthalmology  
Keck School of Medicine  
University of Southern California  
Los Angeles, CA  
Managing Partner, Retina Consultants of Arizona  
Phoenix, AZ

Jay S. Duker, MD  
Professor and Chairman of Ophthalmology  
Director, New England Eye Center  
Tufts Medical Center  
Tufts University School of Medicine  
New England Eye Center  
Boston, MA

Justis P. Ehlers, MD  
The Norman C. and Donna L. Harbert Endowed Chair of Ophthalmic Research  
Cole Eye Institute, Cleveland Clinic  
Cleveland, OH

Michel E. Farah, MD  
Professor of Ophthalmology  
Paulista School of Medicine  
São Paulo State University - UNIFESP  
Director, Centro Oftalmologico Sao Paulo  
Sao Paulo, Brazil

Frederick L. Ferris, III, MD  
Director, Division of Epidemiology and Clinical Applications  
National Eye Institute/National Institutes of Health  
Bethesda, MD

Cedric G. Francois, MD, PhD  
Apellis Pharmaceuticals  
Crestwood, KY

K. Bailey Freund, MD  
Clinical Professor of Ophthalmology  
New York University School of Medicine  
Partner, Vitreous Retina Macula Consultants of New York  
New York, New York, NY

Martin Friedlander, MD, PhD  
Professor, Department of Cell and Molecular Biology  
The Scripps Research Institute  
Chief, Retina Services, Division of Ophthalmology, Department of Surgery  
Scrpps Clinic  
President, The Lowy Medical Research Institute  
La Jolla, CA

Ninel Z. Gregori, MD  
Associate Professor of Clinical Ophthalmology  
Bascom Palmer Eye Institute  
University of Miami Miller School of Medicine  
Miami, FL

Jeffrey S. Heier, MD  
Co-President and Medical Director  
Ophthalmic Consultants of Boston  
Boston, MA

David R. Hinton, MD  
Professor of Ophthalmology  
Keck School of Medicine  
University of Southern California  
Los Angeles, CA

Frederick L. Ferris, III, MD  
Director, Division of Epidemiology and Clinical Applications  
National Eye Institute/National Institutes of Health  
Bethesda, MD

K. Bailey Freund, MD  
Clinical Professor of Ophthalmology  
New York University School of Medicine  
Partner, Vitreous Retina Macula Consultants of New York  
New York, New York, NY

Martin Friedlander, MD, PhD  
Professor, Department of Cell and Molecular Biology  
The Scripps Research Institute  
Chief, Retina Services, Division of Ophthalmology, Department of Surgery  
Scrpps Clinic  
President, The Lowy Medical Research Institute  
La Jolla, CA

Ninel Z. Gregori, MD  
Associate Professor of Clinical Ophthalmology  
Bascom Palmer Eye Institute  
University of Miami Miller School of Medicine  
Miami, FL

Jeffrey S. Heier, MD  
Co-President and Medical Director  
Ophthalmic Consultants of Boston  
Boston, MA

David R. Hinton, MD  
Professor of Ophthalmology  
Keck School of Medicine  
University of Southern California  
Los Angeles, CA
Bascom Palmer Eye Institute
Angiogenesis, Exudation, and Degeneration 2017

DATE
Saturday, February 11, 2017: 7:55 am to 6:30 pm

LOCATION
Mandarin Oriental Miami, Miami, Florida
500 Brickell Key Drive, Miami, FL 33131
Reservations: (800) 526-6566, Direct: (305) 913-8288

Mandarin Oriental Miami is one of America’s finest hotels and recently voted Best Urban Hotel by Miami Herald’s Readers Choice South Florida’s Finest survey-Best of South Florida. Ideally located on prestigious Brickell Key, its deluxe, waterfront location perfectly befits the opulence you’ll find within. The rooms are luxurious, the award-winning restaurants are some of the finest in Miami and the spa is one of the most beautiful in the world. The hotel’s extensive leisure facilities make it the perfect choice for a conference or a holiday in Miami.

HOTEL RESERVATIONS
For hotel information and reservations, please call 305-913-8288 or 800-526-6566.

The special hotel rate for conference attendees is $409 per night for single or double plus tax. The Mandarin Oriental will extend the special group rate for three days prior and three days after the main program dates, subject to availability. Check-in time is 3:00 pm; Check-out time is 12:00 noon.

We suggest you make your hotel reservations as soon as possible as the winter months are the height of South Florida’s tourist season. Bascom Palmer’s preferred room rate will be released after January 11, 2017. Reservations and deposits received after that time are subject to current rates and availability. Please contact the Mandarin Oriental Miami for hotel cancellation policies. For additional information visit: www.mandarinoriental.com/miami

CONFERENCE FEES
Registration rate is $475.
Conference fees include course materials, opening reception, continental breakfast, lunch and refreshment breaks.

CANCELLATION POLICY
Conference tuition, less a $50 cancellation fee, is refundable if notice is received by January 27, 2017. No refunds shall be considered after January 27, 2017 or after sixty (60) days following payment.
ACCREDITATION:
The University of Miami Leonard M. Miller School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION:
The University of Miami Leonard M. Miller School of Medicine designates this live activity for a maximum of 9.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURE AND CONFLICT OF INTEREST RESOLUTION:
All conflicts of interest of any individual(s) in a position to control the content of this CME activity will be identified and resolved prior to this educational activity being provided. Disclosure about provider and faculty relationships, or the lack thereof, will be provided to learners.

SERVICES FOR THE DISABLED
If special arrangements are required for an individual with a disability to attend this conference, please contact Karen Davila at (305) 326-6110 on or before January 27, 2017.

REGISTRATION
Space is limited. Please register early.

To register by internet: Please visit: http://bascompalmer.org/cme/angiogenesis/registration

To register by mail: Please complete the registration form and return with your check or credit card payment to:
Bascom Palmer Eye Institute
Department of Continuing Medical Education
1400 NW 10th Ave., Suite 508
Miami, FL 33136 (Att: Karen Davila)

To register by fax: Please complete the registration form and return with your credit card payment to (305) 326-6518.

For more information contact:
Bascom Palmer Eye Institute
Department of Continuing Medical Education at (305) 326-6110 / Email: bascompalmercme@miami.edu

www.bascompalmer.org
REGISTRATION FORM

Bascom Palmer Eye Institute
Angiogenesis, Exudation, and Degeneration 2017

Saturday, February 11, 2017
Registration is limited, so please register early.

Last Name / First Name (as you want it to appear on name badge) / Degree

Last Four Digits of Social Security Number (for record keeping purposes only)

Specialty / Sub-specialty

Affiliated Institution

Address (Check box if new address)

City/State

Country / Zip or Postal Code

Office phone                                                    Office fax

Email

REGISTRATION: $475

☐ Enclosed is my check made payable to Bascom Palmer Eye Institute–Angiogenesis 2017

☐ Please bill my credit card:
  ☐ Mastercard  ☐ Visa  ☐ American Express

Card number

Security code       Expiration date       Billing zip code

Name on card

Signature

Online: http://bascompalmer.org/cme/angiogenesis/registration

By fax: Please complete this registration form with your credit card payment and fax to (305) 326-6518. By mail: Please complete this registration form and return with your check or credit card payment to:

Bascom Palmer Eye Institute
Continuing Medical Education Department
1400 NW 10th Ave., Suite 508
Miami, FL 33136
(Attn: Karen Davila)